| Name | Title | Contact Details |
|---|
MANUFACTURING Philosophy The TRC team understands that the actions required to be a successful pharmaceutical manufacturer are more than just completing repetitive and highly detailed tasks accurately; it is the understanding that we...
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.
OnKure, Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure`s drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.
A physician led and owned organization committed to improving healthcare by supporting independent rheumatology practices across the nation and providing innovative technology to lower healthcare costs for providers and patients
Trimeris is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.